Vanguard Group
INBX icon

Vanguard Group’s Inhibrx INBX Stock Holding History

Vanguard Group’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$49.2M Buy
623,084
+28,166
+5% +$1.92M ﹤0.01% 2171
2025
Q3 		$20M Sell
594,918
-3,530
-0.6% -$86.9K ﹤0.01% 2625
2025
Q2 		$8.54M Buy
598,448
+10,125
+2% +$131K ﹤0.01% 2988
2025
Q1 		$8.23M Sell
588,323
-19,398
-3% -$263K ﹤0.01% 2954
2024
Q4 		$9.36M Buy
607,721
+77,663
+15% +$1.18M ﹤0.01% 2996
2024
Q3 		$8.3M Buy
530,058
+52,030
+11% +$731K ﹤0.01% 3053
2024
Q2 		$6.77M Buy
+478,028
New +$7.47M ﹤0.01% 3115

Other funds holding INBX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Vanguard Group's INBX Position: Q4 2025 in Review

Vanguard Group increased its Inhibrx (INBX) stake by 4.7% in Q4 2025, buying an estimated $1.92M and bringing the position to 623,084 shares worth $49.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2171.

Vanguard Group first reported a position in INBX in Q2 2024 and has held it in 7 quarters since. 138 funds tracked by Wall St. Rank hold INBX as of Q4 2025.

  • Vanguard Group held 623,084 shares of Inhibrx worth $49.2M as of Q4 2025.
  • Vanguard Group bought 28,166 Inhibrx shares in Q4 2025, an estimated $1.92M.
  • Inhibrx made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2171 holding.
  • Vanguard Group first reported a position in Inhibrx in Q2 2024 and has held it in 7 quarters since.
  • 138 funds tracked by Wall St. Rank held Inhibrx as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.